Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Biomarin Pharmaceutical Inc
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA
Business
Feb 25 2025
5 min read

BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA

SAN RAFAEL, Calif., Feb. 25, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4, 2025, at 6:50 AM PT / 9:50 AM ET in Boston, MA.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. 

About BioMarinBioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com

Contacts:

Investors

Media

Traci McCarty

Marni Kottle

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558 

(650) 374-2803

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-present-at-the-td-cowen-45th-annual-healthcare-conference-on-tuesday-march-4-at-650-am-pt--950-am-et-in-boston-ma-302383918.html

SOURCE BioMarin Pharmaceutical Inc.